Cardiovascular

Latest News

Q&A with Sid Patel, MD
Abelacimab Demonstrates Safety and Efficacy for Patients With AFib of All Ages: Sid Patel, MD

April 24th 2025

The continued success of abelacimab throughout the AZALEA-TIMI 71 trials helps draw the drug closer to FDA approval, stated Sid Patel, MD.

One's ZIP code can greatly influence care access | image credit: Syda Productions - stock.adobe.com
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health

April 18th 2025

Jeremy Wigginton, MD
Lp(a) and Getting a Head Start Against Heart Disease: Jeremy Wigginton, MD

April 8th 2025

ACC.25
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment

April 4th 2025

Heart disease is, and has been, the number 1 cause of death for Americans over the last century | image credit: Thirakun - stock.adobe.com
Digital Solutions Can Transform CVD Care, Prevention

April 2nd 2025

Lipoprotein(a) and Cardiovascular Risk

Learn about more about lipoprotein(a), including how to improve patient outcomes through better screening and management.

AJMC Peer Exchange logo
Continuing Medical Education
View All
April 25th 2025

Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment

1.5 Credits / Cardiology, Neurology, Rare Diseases
April 25th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
April 25th 2025

Evidence-Based Guidelines Point to Leap in Care for Hypertrophic Cardiomyopathy

1.0 Credit / Cardiology

More News

Carotid Artery Lipid Core Associated With CVD, Independent of Artery Wall Thickness
November 27th 2020

Carotid Artery Lipid Core Associated With CVD, Independent of Artery Wall Thickness

Samantha DiGrande
It remains unclear whether measures of magnetic resonance imaging plaque characteristics are associated with cardiovascular disease events independent of plaque burden at the population level.
Association Between Clogged Arteries and Body Size Phenotype? Study Finds, “It Varies”
November 25th 2020

Association Between Clogged Arteries and Body Size Phenotype? Study Finds, “It Varies”

Samantha DiGrande
Cardiac graphic
November 17th 2020

Study Highlights Finerenone Benefits in CV Outcomes for Patients With CKD

Allison Inserro
Finerenone may represent an important step forward to reducing cardiac illness and death in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), the study said.
Lincoff
November 15th 2020

Fish Oil Debate Continues as Study Finds No Risk Reduction From Omega-3 Combo

Mary Caffrey
The investigator of the STRENGTH study says findings raise questions about the landmark REDUCE-IT trial, but other evidence suggests the drugs involved are different.
Site Logo
November 10th 2020

AHA Telemetry Guidelines Improve Telemetry Utilization in the Inpatient Setting

Sima S. Pendharkar, MD, MPH Ibrahim B. Barry, MD, MPH Saikrishna Patibandla, MD, MS Tiffany I. Leung, MD, MPH Amol Gupta, MBBS Aung Naing Lin, MD James A. Gasperino, MD, PhD, MPH
Using Plan-Do-Study-Act cycles, the studied intervention reduced hospital inpatient telemetry time by 51.25% while increasing American Heart Association (AHA) guideline–based usage.
Site Logo
November 10th 2020

Telemetry: Appropriateness of Initial Assignment and Duration in Nonintensive Setting

Rohit Chaudhary, MIS Thomas Kingsley, MD Sauradeep Sarkar, MD Joseph Carrington, DO Galo M. Sanchez Palacios, MD Tushar Sharma, MD Jalaj Garg, MD Rahul Chaudhary, MD, MBA
The authors report overutilization of telemetry monitoring in a community setting, increasing the cost of health care and potential harm to patients with unnecessary interventions.
Site Logo
October 19th 2020

Social Determinants of Health Score: Does It Help Identify Those at Higher Cardiovascular Risk?

Ana Palacio, MD, MPH Ruaa Mansi, MD, MPH David Seo, MD Maritza Suarez, MD Sylvia Garay, MD Heidy Medina, MPH Fei Tang, PhD Leonardo Tamariz, MD, MPH
Calculating a social score is feasible and it predicts cardiovascular outcomes. In order to do this, institutions have to collect social determinants of health.
Better Strategies to Reduce Cardiovascular Events
September 16th 2020

Better Strategies to Reduce Cardiovascular Events

Clinical Pathways for Cardiovascular Disease Management
September 16th 2020

Clinical Pathways for Cardiovascular Disease Management

CVD: Cost-Effectiveness Data and Treatment Selection
September 16th 2020

CVD: Cost-Effectiveness Data and Treatment Selection

Cost-Effectiveness Data and Pricing of Icosapent Ethyl
September 16th 2020

Cost-Effectiveness Data and Pricing of Icosapent Ethyl

CV Risk Reduction and Coverage of Therapies
September 16th 2020

CV Risk Reduction and Coverage of Therapies

Cardiovascular Disease Treatment Decisions and Cost
September 16th 2020

Cardiovascular Disease Treatment Decisions and Cost

Cost-Effectiveness and Cardiovascular Risk
September 16th 2020

Cost-Effectiveness and Cardiovascular Risk

Implications for Treating Patients With Icosapent Ethyl
September 16th 2020

Implications for Treating Patients With Icosapent Ethyl

Coronary Plaque Regression and CV Risk
September 16th 2020

Coronary Plaque Regression and CV Risk

Interim Analysis of EVAPORATE
September 16th 2020

Interim Analysis of EVAPORATE

The REDUCE-IT Study and CV Risk
September 16th 2020

The REDUCE-IT Study and CV Risk

Targeting Triglycerides to Reduce CV Risk
September 16th 2020

Targeting Triglycerides to Reduce CV Risk

Dyslipidemia: Cost-Utilization of PCSK9 Inhibitors
September 16th 2020

Dyslipidemia: Cost-Utilization of PCSK9 Inhibitors

PCSK9 Inhibitors and CV Risk
September 16th 2020

PCSK9 Inhibitors and CV Risk

Statin Therapy: Risk for Future CV Events
September 16th 2020

Statin Therapy: Risk for Future CV Events

Statin Therapy for LDL Reduction and CV Risk
September 16th 2020

Statin Therapy for LDL Reduction and CV Risk

Dyslipidemia: Strategies Used to Reduce CV Risk
September 16th 2020

Dyslipidemia: Strategies Used to Reduce CV Risk

Cardiovascular Risk Management
September 16th 2020

Cardiovascular Risk Management

LDL Cholesterol Lowering and CV Risk
September 16th 2020

LDL Cholesterol Lowering and CV Risk

Risk Assessment for Cardiovascular Disease
September 16th 2020

Risk Assessment for Cardiovascular Disease

Economic Burden of Cardiovascular Disease
September 16th 2020

Economic Burden of Cardiovascular Disease

Vascepa Brings 36% Drop in Surgeries to Restore Blood Flow, Results Show
July 25th 2020

Vascepa Brings 36% Drop in Surgeries to Restore Blood Flow, Results Show

Mary Caffrey
Deepak L. Bhatt, MD, MPH, of Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School, presented the latest round of data from REDUCE-IT at the American Society of Preventive Cardiology Virtual Summit 2020 this morning
Reduced Risk of Second Stroke With Ticagrelor Plus Aspirin Than Aspirin Alone
July 17th 2020

Reduced Risk of Second Stroke With Ticagrelor Plus Aspirin Than Aspirin Alone

Mary Caffrey
Transient ischemic attack is a common form of stroke, and 1 in 4 stroke survivors go on to experience a second stroke—most within the first month.
<1
...
34567891011
...
23>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo